{"id":1955,"date":"2020-09-17T23:10:15","date_gmt":"2020-09-17T23:10:15","guid":{"rendered":"\/\/smallcapscn.x5view.co\/?p=1955"},"modified":"2023-08-29T18:01:58","modified_gmt":"2023-08-29T18:01:58","slug":"immutep-improved-results-two-parallel-clinical-trials-lead-drug-eftilagimod-alpha","status":"publish","type":"post","link":"https:\/\/smallcapscn.x5view.co\/?p=1955","title":{"rendered":"Immutep\u516c\u5e03\u4e86\u4e24\u4e2a\u5e73\u884c\u4e34\u5e8a\u8bd5\u9a8c\u5bf9\u5148\u5bfc\u836f\u7269eftilagimod alpha\u7684\u6539\u8fdb\u7ed3\u679c"},"content":{"rendered":"<p>\u751f\u7269\u6280\u672f\u516c\u53f8<a href=\"http:\/\/smallcaps-production.test\/stocks\/?symbol=IMM&amp;lang=cn\">Immutep (ASX: IMM)<\/a>\u516c\u5e03\u4e86\u5176\u5148\u5bfc\u836f\u7269eftilagimod alpha\u7684\u4e24\u9879\u5e73\u884c\u4e34\u5e8a\u7814\u7a76\u7ed3\u679c\uff0c\u79f0\u201c\u6539\u5584\u7684\u7ed3\u679c\u201d\u548c\u201c\u4ee4\u4eba\u9f13\u821e\u7684\u201d\u65e9\u671f\u6297\u80bf\u7624\u6d3b\u6027\u6807\u5fd7\u7740\u5404\u79cd\u764c\u75c7\u9002\u5e94\u75c7\u5bf9\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242(ICI)\u6cbb\u7597\u4e0d\u654f\u611f\u3002<\/p>\n<p>Immutep\u7684INSIGHT-004\u4e00\u671f\u4e34\u5e8a\u8bd5\u9a8c\u662f\u5728\u5fb7\u56fdFrankfurt\u4e0e\u5236\u836f\u5de8\u5934Merck\u548cPfizer\u5408\u4f5c\u8fdb\u884c\u7684\u3002<\/p>\n<p>\u8fd9\u4e09\u5bb6\u516c\u53f8\u6b63\u5728\u5171\u540c\u5f00\u53d1\u4e00\u79cd\u540d\u4e3aBavencio\u7684\u5168\u4eba\u7c7b\u5355\u514b\u9686\u6297\u4f53\uff0c\u5e76\u5c06avelumab\u8054\u5408\u5546\u4e1a\u5316\u3002<\/p>\n<p>Immutep\u7684INSIGHT-004\u836f\u7269\u662f\u7814\u7a76\u8005\u53d1\u8d77\u7684INSIGHT\u8bd5\u9a8c\u7684\u7b2c\u56db\u90e8\u5206\u3002<\/p>\n<p>\u8be5\u8bd5\u9a8c\u65e8\u5728\u8bc4\u4f30efti\u4e0eavelumab\u8054\u5408\u5e94\u7528\u4e8e12\u540d\u60a3\u6709\u4e0d\u540c\u5b9e\u4f53\u80bf\u7624(\u4e3b\u8981\u662f\u80c3\u80a0\u9053\u80bf\u7624)\u7684\u60a3\u8005\u3002<\/p>\n<p>Immutep\u5728\u4e00\u4efd\u5e02\u573a\u58f0\u660e\u4e2d\u8868\u793a\uff0c41.7%\u7684\u60a3\u8005\u5bf9\u8be5\u7597\u6cd5\u8868\u73b0\u51fa\u90e8\u5206\u53cd\u5e94\uff0c\u800c\u6b64\u524d\u8bb0\u5f55\u7684\u8fd9\u4e00\u6bd4\u4f8b\u4e3a33%\u3002\u6b64\u5916\uff0c\u8be5\u8bd5\u9a8c\u8868\u660e\u75be\u75c5\u63a7\u5236\u7387\u4e3a50%\u3002<\/p>\n<p>\u6628\u5929\u5728\u56fd\u4f1aESMO\u865a\u62df\u6f14\u793a,\u4e86\u89e3- 004\u8bd5\u9a8c\u8c03\u67e5\u5458\u548cIKF\u4e3b\u4efb\u6559\u6388Salah-Eddin Al-Batran\u8868\u793a:\u201c\u4ee4\u4eba\u9f13\u821e\u7684\u662f\u770b\u5230\u7684\u8303\u56f4\u4e0d\u540c\u7684\u56fa\u4f53\u764c\u75c7\u60a3\u8005\u5e94\u5bf9efti\u548cavelumab,\u5305\u62ecPD-L1-negative\u5bab\u9888\u764c\u3001\u9cde\u72b6\u809b\u95e8\u7ec6\u80de\u764c\u548c\u95f4\u76ae\u7624\u3002\u8fd9\u4e9b\u80bf\u7624\u5bf9\u514d\u75ab\u68c0\u67e5\u70b9\u6cbb\u7597\u6ca1\u6709\u5178\u578b\u53cd\u5e94\uff0c\u9700\u8981\u8fdb\u4e00\u6b65\u7814\u7a76\u3002\u201d<\/p>\n<h2>\u76ae\u80a4\u764c\u7684\u7814\u7a76<\/h2>\n<p>\u5e76\u884cINSIGHT-004,Immutep\u4e5f\u8fdb\u5c55TACTI-002\u8bd5\u9a8c,\u4e5f\u4e0eMerck\u516c\u53f8\u5408\u4f5c,\u8fdb\u884c\u8bc4\u4f30\u7684\u7ed3\u5408efti\u4e0e\u9ed8\u514b\u836f\u7269pembrolizumab,\u66f4\u597d\u5730\u79f0\u4e3aKeytruda,\u7ea6109\u60a3\u8005\u4e8c\u7ebf\u5934\u9888\u90e8\u9cde\u72b6\u7ec6\u80de\u764c\u6216\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u5728\u7b2c\u4e00\u548c\u7b2c\u4e8c\u7ebf\u3002<\/p>\n<p>\u8be5\u8bd5\u9a8c\u662f\u7b2c\u4e8c\u9636\u6bb5\uff0c\u7531Simon\u8fdb\u884c\u7684\u4e24\u9636\u6bb5\u3001\u975e\u6bd4\u8f83\u6027\u3001\u5f00\u653e\u6807\u7b7e\u3001\u5355\u81c2\u3001\u591a\u4e2d\u5fc3\u4e34\u5e8a\u7814\u7a76\uff0c\u5728\u6fb3\u5927\u5229\u4e9a\u3001\u6b27\u6d32\u3001\u82f1\u56fd\u548c\u7f8e\u56fd\u7684\u591a\u8fbe12\u4e2a\u4e2d\u5fc3\u8fdb\u884c\u3002<\/p>\n<p>\u60a3\u8005\u53c2\u4e0e\u4e09\u4e2a\u90e8\u5206:A\u90e8\u5206\u8c03\u67e5\u4e00\u7ebf\u975e\u5c0f\u7ec6\u80de\u80ba\u764c(NSCLC) PD-X\u521d\u53d1\uff0cB\u90e8\u5206\u8c03\u67e5\u4e8c\u7ebf\u975e\u5c0f\u7ec6\u80de\u80ba\u764cPD-X\u96be\u6cbb\uff0cC\u90e8\u5206\u8c03\u67e5\u4e8c\u7ebf\u5934\u9888\u90e8\u9cde\u72b6\u7ec6\u80de\u764c(HNSCC) PD-X\u521d\u53d1\u3002<\/p>\n<p>INSIGHT-004\u663e\u793a\uff0c\u57286\u4e2a\u6708\u7684\u6cbb\u7597\u4e2d\uff0c47.1%\u7684\u60a3\u8005\u65e0\u8fdb\u5c55\uff0ciORR\u7ef4\u6301\u7387\u4e3a38.9%\u3002\u7ed3\u679c\u8fd8\u663e\u793a\uff0c2\u4f8b\u60a3\u8005\u8bb0\u5f55\u5b8c\u5168\u7f13\u89e3\u548c5\u4f8b\u60a3\u8005\u8bb0\u5f55\u90e8\u5206\u7f13\u89e3\u3002<\/p>\n<p>\u8be5\u7814\u7a76\u7684\u9996\u5e2d\u7814\u7a76\u5458Martin Foster\u535a\u58eb\u8868\u793a\uff0c\u7814\u7a76\u7ed3\u679c\u4ee4\u4eba\u9f13\u821e\uff0c\u5e76\u6709\u6240\u6539\u5584\uff0c\u7279\u522b\u662f\u5bf9\u4e8e\u8010\u836f\u665a\u671f\u5934\u9888\u764c\uff0c\u8fd9\u4e9b\u764c\u75c7\u5bf9\u5176\u4ed6\u7597\u6cd5\u7684\u53cd\u5e94\u53ef\u80fd\u6027\u5f88\u5c0f\u3002<\/p>\n<p>\u6b64\u5916\uff0c\u53cd\u5e94\u7684\u6301\u4e45\u6027\u548c\u4e24\u4e2a\u5b8c\u5168\u53cd\u5e94\u7684\u60a3\u8005\u88ab\u63cf\u8ff0\u4e3a\u201c\u975e\u5e38\u6709\u5e0c\u671b\u7684\u4fe1\u53f7\u201d\uff0c\u56e0\u6b64\u6709\u7406\u7531\u8fdb\u884c\u8fdb\u4e00\u6b65\u7684\u7814\u7a76\u3002<\/p>\n<p>\u201c\u636e\u62a5\u9053\uff0cefti\u548cpembrolizumab\u7684\u8054\u5408\u5e94\u7528\u5728HNSCC\u548cNSCLC\u60a3\u8005\u4e2d\u9f13\u821e\u4e86\u65e0\u8fdb\u5c55\u751f\u5b58\uff0c\u6539\u5584\u4e86\u72ec\u7acb\u5386\u53f2\u8bd5\u9a8c\u7684\u7ed3\u679c\uff0c\u201dImmutep\u7684\u9996\u5e2d\u79d1\u5b66\u548c\u533b\u7597\u5b98Frederic Triebel\u535a\u58eb\u8bf4\u3002<\/p>\n<p>\u201c\u5728\u53ef\u6bd4\u7814\u7a76\u4e2d\uff0c\u63a5\u53d7pembrolizumab\u5355\u836f\u6cbb\u7597\u7684HNSCC\u60a3\u8005\u7684PFS\u4e3a2.1\u4e2a\u6708\uff0c\u5982\u679c\u7ed9\u4e88\u5316\u7597\u5219\u4e3a2.3\u4e2a\u6708\u3002\u201d<\/p>\n<p>\u4e0e\u6b64\u76f8\u6bd4\uff0c\u5728TACTI-002\u8bd5\u9a8c\u4e2d\uff0cHNSCC\u60a3\u8005\u7684PFS\u4e3a4.3\u4e2a\u6708\u3002\u5728\u4e24\u7ec4\u60a3\u8005\u4e2d\u90fd\u6709\u975e\u5e38\u597d\u7684\u6301\u4e45\u7684\u53cd\u5e94\uff0c\u800c\u4e14\u4e0d\u4f7f\u7528\u5316\u7597\uff0c\u8fd9\u5bf9efti\u6765\u8bf4\u662f\u975e\u5e38\u4ee4\u4eba\u9f13\u821e\u7684\u3002\u201d<\/p>\n<p>Immutep\u5e0c\u671b\u5728\u4eca\u5e74\u665a\u4e9b\u65f6\u5019\u7684\u4e00\u6b21\u4f1a\u8bae\u4e0a\u62a5\u544a\u7b2c\u4e8c\u671f\u8bd5\u9a8c\u7684\u9996\u6279\u6570\u636e\u548c\u7b2c\u4e00\u671f\u8bd5\u9a8c\u7684\u66f4\u6210\u719f\u6570\u636e\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u751f\u7269\u6280\u672f\u516c\u53f8Immutep (ASX: IMM)\u516c\u5e03\u4e86\u5176\u5148\u5bfc\u836f\u7269eftilagimod alpha\u7684\u4e24\u9879\u5e73\u884c\u4e34\u5e8a\u7814\u7a76\u7ed3\u679c\uff0c\u79f0\u201c\u6539\u5584\u7684\u7ed3\u679c\u201d\u548c\u201c\u4ee4\u4eba\u9f13\u821e\u7684\u201d\u65e9\u671f\u6297\u80bf\u7624\u6d3b\u6027\u6807\u5fd7\u7740\u5404\u79cd\u764c\u75c7\u9002\u5e94\u75c7\u5bf9\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242(ICI)\u6cbb\u7597\u4e0d\u654f\u611f\u3002 Immutep\u7684INSIGHT-004\u4e00\u671f\u4e34\u5e8a\u8bd5\u9a8c\u662f\u5728\u5fb7\u56fdFrankfurt\u4e0e\u5236\u836f\u5de8\u5934Merck\u548cPfizer\u5408\u4f5c\u8fdb\u884c\u7684\u3002 \u8fd9\u4e09\u5bb6\u516c\u53f8\u6b63\u5728\u5171\u540c\u5f00\u53d1\u4e00\u79cd\u540d\u4e3aBavencio\u7684\u5168\u4eba\u7c7b\u5355\u514b\u9686\u6297\u4f53\uff0c\u5e76\u5c06avelumab\u8054\u5408\u5546\u4e1a\u5316\u3002 Immutep\u7684INSIGHT-004\u836f\u7269\u662f\u7814\u7a76\u8005\u53d1\u8d77\u7684INSIGHT\u8bd5\u9a8c\u7684\u7b2c\u56db\u90e8\u5206\u3002 \u8be5\u8bd5\u9a8c\u65e8\u5728\u8bc4\u4f30efti\u4e0eavelumab\u8054\u5408\u5e94\u7528\u4e8e12\u540d\u60a3\u6709\u4e0d\u540c\u5b9e\u4f53\u80bf\u7624(\u4e3b\u8981\u662f\u80c3\u80a0\u9053\u80bf\u7624)\u7684\u60a3\u8005\u3002 Immutep\u5728\u4e00\u4efd\u5e02\u573a\u58f0\u660e\u4e2d\u8868\u793a\uff0c41.7%\u7684\u60a3\u8005\u5bf9\u8be5\u7597\u6cd5\u8868\u73b0\u51fa\u90e8\u5206\u53cd\u5e94\uff0c\u800c\u6b64\u524d\u8bb0\u5f55\u7684\u8fd9\u4e00\u6bd4\u4f8b\u4e3a33%\u3002\u6b64\u5916\uff0c\u8be5\u8bd5\u9a8c\u8868\u660e\u75be\u75c5\u63a7\u5236\u7387\u4e3a50%\u3002 \u6628\u5929\u5728\u56fd\u4f1aESMO\u865a\u62df\u6f14\u793a,\u4e86\u89e3- 004\u8bd5\u9a8c\u8c03\u67e5\u5458\u548cIKF\u4e3b\u4efb\u6559\u6388Salah-Eddin Al-Batran\u8868\u793a:\u201c\u4ee4\u4eba\u9f13\u821e\u7684\u662f\u770b\u5230\u7684\u8303\u56f4\u4e0d\u540c\u7684\u56fa\u4f53\u764c\u75c7\u60a3\u8005\u5e94\u5bf9efti\u548cavelumab,\u5305\u62ecPD-L1-negative\u5bab\u9888\u764c\u3001\u9cde\u72b6\u809b\u95e8\u7ec6\u80de\u764c\u548c\u95f4\u76ae\u7624\u3002\u8fd9\u4e9b\u80bf\u7624\u5bf9\u514d\u75ab\u68c0\u67e5\u70b9\u6cbb\u7597\u6ca1\u6709\u5178\u578b\u53cd\u5e94\uff0c\u9700\u8981\u8fdb\u4e00\u6b65\u7814\u7a76\u3002\u201d \u76ae\u80a4\u764c\u7684\u7814\u7a76 \u5e76\u884cINSIGHT-004,Immutep\u4e5f\u8fdb\u5c55TACTI-002\u8bd5\u9a8c,\u4e5f\u4e0eMerck\u516c\u53f8\u5408\u4f5c,\u8fdb\u884c\u8bc4\u4f30\u7684\u7ed3\u5408efti\u4e0e\u9ed8\u514b\u836f\u7269pembrolizumab,\u66f4\u597d\u5730\u79f0\u4e3aKeytruda,\u7ea6109\u60a3\u8005\u4e8c\u7ebf\u5934\u9888\u90e8\u9cde\u72b6\u7ec6\u80de\u764c\u6216\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u5728\u7b2c\u4e00\u548c\u7b2c\u4e8c\u7ebf\u3002 \u8be5\u8bd5\u9a8c\u662f\u7b2c\u4e8c\u9636\u6bb5\uff0c\u7531Simon\u8fdb\u884c\u7684\u4e24\u9636\u6bb5\u3001\u975e\u6bd4\u8f83\u6027\u3001\u5f00\u653e\u6807\u7b7e\u3001\u5355\u81c2\u3001\u591a\u4e2d\u5fc3\u4e34\u5e8a\u7814\u7a76\uff0c\u5728\u6fb3\u5927\u5229\u4e9a\u3001\u6b27\u6d32\u3001\u82f1\u56fd\u548c\u7f8e\u56fd\u7684\u591a\u8fbe12\u4e2a\u4e2d\u5fc3\u8fdb\u884c\u3002 \u60a3\u8005\u53c2\u4e0e\u4e09\u4e2a\u90e8\u5206:A\u90e8\u5206\u8c03\u67e5\u4e00\u7ebf\u975e\u5c0f\u7ec6\u80de\u80ba\u764c(NSCLC) PD-X\u521d\u53d1\uff0cB\u90e8\u5206\u8c03\u67e5\u4e8c\u7ebf\u975e\u5c0f\u7ec6\u80de\u80ba\u764cPD-X\u96be\u6cbb\uff0cC\u90e8\u5206\u8c03\u67e5\u4e8c\u7ebf\u5934\u9888\u90e8\u9cde\u72b6\u7ec6\u80de\u764c(HNSCC) PD-X\u521d\u53d1\u3002 INSIGHT-004\u663e\u793a\uff0c\u57286\u4e2a\u6708\u7684\u6cbb\u7597\u4e2d\uff0c47.1%\u7684\u60a3\u8005\u65e0\u8fdb\u5c55\uff0ciORR\u7ef4\u6301\u7387\u4e3a38.9%\u3002\u7ed3\u679c\u8fd8\u663e\u793a\uff0c2\u4f8b\u60a3\u8005\u8bb0\u5f55\u5b8c\u5168\u7f13\u89e3\u548c5\u4f8b\u60a3\u8005\u8bb0\u5f55\u90e8\u5206\u7f13\u89e3\u3002 \u8be5\u7814\u7a76\u7684\u9996\u5e2d\u7814\u7a76\u5458Martin Foster\u535a\u58eb\u8868\u793a\uff0c\u7814\u7a76\u7ed3\u679c\u4ee4\u4eba\u9f13\u821e\uff0c\u5e76\u6709\u6240\u6539\u5584\uff0c\u7279\u522b\u662f\u5bf9\u4e8e\u8010\u836f\u665a\u671f\u5934\u9888\u764c\uff0c\u8fd9\u4e9b\u764c\u75c7\u5bf9\u5176\u4ed6\u7597\u6cd5\u7684\u53cd\u5e94\u53ef\u80fd\u6027\u5f88\u5c0f\u3002 \u6b64\u5916\uff0c\u53cd\u5e94\u7684\u6301\u4e45\u6027\u548c\u4e24\u4e2a\u5b8c\u5168\u53cd\u5e94\u7684\u60a3\u8005\u88ab\u63cf\u8ff0\u4e3a\u201c\u975e\u5e38\u6709\u5e0c\u671b\u7684\u4fe1\u53f7\u201d\uff0c\u56e0\u6b64\u6709\u7406\u7531\u8fdb\u884c\u8fdb\u4e00\u6b65\u7684\u7814\u7a76\u3002 \u201c\u636e\u62a5\u9053\uff0cefti\u548cpembrolizumab\u7684\u8054\u5408\u5e94\u7528\u5728HNSCC\u548cNSCLC\u60a3\u8005\u4e2d\u9f13\u821e\u4e86\u65e0\u8fdb\u5c55\u751f\u5b58\uff0c\u6539\u5584\u4e86\u72ec\u7acb\u5386\u53f2\u8bd5\u9a8c\u7684\u7ed3\u679c\uff0c\u201dImmutep\u7684\u9996\u5e2d\u79d1\u5b66\u548c\u533b\u7597\u5b98Frederic Triebel\u535a\u58eb\u8bf4\u3002 \u201c\u5728\u53ef\u6bd4\u7814\u7a76\u4e2d\uff0c\u63a5\u53d7pembrolizumab\u5355\u836f\u6cbb\u7597\u7684HNSCC\u60a3\u8005\u7684PFS\u4e3a2.1\u4e2a\u6708\uff0c\u5982\u679c\u7ed9\u4e88\u5316\u7597\u5219\u4e3a2.3\u4e2a\u6708\u3002\u201d \u4e0e\u6b64\u76f8\u6bd4\uff0c\u5728TACTI-002\u8bd5\u9a8c\u4e2d\uff0cHNSCC\u60a3\u8005\u7684PFS\u4e3a4.3\u4e2a\u6708\u3002\u5728\u4e24\u7ec4\u60a3\u8005\u4e2d\u90fd\u6709\u975e\u5e38\u597d\u7684\u6301\u4e45\u7684\u53cd\u5e94\uff0c\u800c\u4e14\u4e0d\u4f7f\u7528\u5316\u7597\uff0c\u8fd9\u5bf9efti\u6765\u8bf4\u662f\u975e\u5e38\u4ee4\u4eba\u9f13\u821e\u7684\u3002\u201d Immutep\u5e0c\u671b\u5728\u4eca\u5e74\u665a\u4e9b\u65f6\u5019\u7684\u4e00\u6b21\u4f1a\u8bae\u4e0a\u62a5\u544a\u7b2c\u4e8c\u671f\u8bd5\u9a8c\u7684\u9996\u6279\u6570\u636e\u548c\u7b2c\u4e00\u671f\u8bd5\u9a8c\u7684\u66f4\u6210\u719f\u6570\u636e\u3002<\/p>\n","protected":false},"author":5,"featured_media":9407,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[303],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v17.3 (Yoast SEO v21.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Immutep\u516c\u5e03\u4e86\u4e24\u4e2a\u5e73\u884c\u4e34\u5e8a\u8bd5\u9a8c\u5bf9\u5148\u5bfc\u836f\u7269eftilagimod alpha\u7684\u6539\u8fdb\u7ed3\u679c<\/title>\n<meta name=\"description\" content=\"\u751f\u7269\u6280\u672f\u516c\u53f8Immutep (ASX: IMM)\u516c\u5e03\u4e86\u5176\u5148\u5bfc\u836f\u7269eftilagimod alpha\u7684\u4e24\u9879\u5e73\u884c\u4e34\u5e8a\u7814\u7a76\u7ed3\u679c\uff0c\u79f0\u201c\u6539\u5584\u7684\u7ed3\u679c\u201d\u548c\u201c\u4ee4\u4eba\u9f13\u821e\u7684\u201d\u65e9\u671f\u6297\u80bf\u7624\u6d3b\u6027\u6807\u5fd7\u7740\u5404\u79cd\u764c\u75c7\u9002\u5e94\u75c7\u5bf9\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242(ICI)\u6cbb\u7597\u4e0d\u654f\u611f\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immutep\u516c\u5e03\u4e86\u4e24\u4e2a\u5e73\u884c\u4e34\u5e8a\u8bd5\u9a8c\u5bf9\u5148\u5bfc\u836f\u7269eftilagimod alpha\u7684\u6539\u8fdb\u7ed3\u679c\" \/>\n<meta property=\"og:description\" content=\"\u751f\u7269\u6280\u672f\u516c\u53f8Immutep (ASX: IMM)\u516c\u5e03\u4e86\u5176\u5148\u5bfc\u836f\u7269eftilagimod alpha\u7684\u4e24\u9879\u5e73\u884c\u4e34\u5e8a\u7814\u7a76\u7ed3\u679c\uff0c\u79f0\u201c\u6539\u5584\u7684\u7ed3\u679c\u201d\u548c\u201c\u4ee4\u4eba\u9f13\u821e\u7684\u201d\u65e9\u671f\u6297\u80bf\u7624\u6d3b\u6027\u6807\u5fd7\u7740\u5404\u79cd\u764c\u75c7\u9002\u5e94\u75c7\u5bf9\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242(ICI)\u6cbb\u7597\u4e0d\u654f\u611f\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/immutep-improved-results-two-parallel-clinical-trials-lead-drug-eftilagimod-alpha\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-17T23:10:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T18:01:58+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/09\/Immutep-ASX-IMM-parallel-clinical-trials-lead-drug-eftilagimod-alpha-cancer.jpg\" \/>\n<meta name=\"author\" content=\"Small Caps\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Immutep\u516c\u5e03\u4e86\u4e24\u4e2a\u5e73\u884c\u4e34\u5e8a\u8bd5\u9a8c\u5bf9\u5148\u5bfc\u836f\u7269eftilagimod alpha\u7684\u6539\u8fdb\u7ed3\u679c\" \/>\n<meta name=\"twitter:description\" content=\"\u751f\u7269\u6280\u672f\u516c\u53f8Immutep (ASX: IMM)\u516c\u5e03\u4e86\u5176\u5148\u5bfc\u836f\u7269eftilagimod alpha\u7684\u4e24\u9879\u5e73\u884c\u4e34\u5e8a\u7814\u7a76\u7ed3\u679c\uff0c\u79f0\u201c\u6539\u5584\u7684\u7ed3\u679c\u201d\u548c\u201c\u4ee4\u4eba\u9f13\u821e\u7684\u201d\u65e9\u671f\u6297\u80bf\u7624\u6d3b\u6027\u6807\u5fd7\u7740\u5404\u79cd\u764c\u75c7\u9002\u5e94\u75c7\u5bf9\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242(ICI)\u6cbb\u7597\u4e0d\u654f\u611f\u3002\" \/>\n<meta name=\"twitter:image\" content=\"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/09\/Immutep-ASX-IMM-parallel-clinical-trials-lead-drug-eftilagimod-alpha-cancer.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Small Caps\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/immutep-improved-results-two-parallel-clinical-trials-lead-drug-eftilagimod-alpha\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/immutep-improved-results-two-parallel-clinical-trials-lead-drug-eftilagimod-alpha\/\",\"name\":\"Immutep\u516c\u5e03\u4e86\u4e24\u4e2a\u5e73\u884c\u4e34\u5e8a\u8bd5\u9a8c\u5bf9\u5148\u5bfc\u836f\u7269eftilagimod alpha\u7684\u6539\u8fdb\u7ed3\u679c\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2020-09-17T23:10:15+00:00\",\"dateModified\":\"2023-08-29T18:01:58+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74\"},\"description\":\"\u751f\u7269\u6280\u672f\u516c\u53f8Immutep (ASX: IMM)\u516c\u5e03\u4e86\u5176\u5148\u5bfc\u836f\u7269eftilagimod alpha\u7684\u4e24\u9879\u5e73\u884c\u4e34\u5e8a\u7814\u7a76\u7ed3\u679c\uff0c\u79f0\u201c\u6539\u5584\u7684\u7ed3\u679c\u201d\u548c\u201c\u4ee4\u4eba\u9f13\u821e\u7684\u201d\u65e9\u671f\u6297\u80bf\u7624\u6d3b\u6027\u6807\u5fd7\u7740\u5404\u79cd\u764c\u75c7\u9002\u5e94\u75c7\u5bf9\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242(ICI)\u6cbb\u7597\u4e0d\u654f\u611f\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/immutep-improved-results-two-parallel-clinical-trials-lead-drug-eftilagimod-alpha\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/immutep-improved-results-two-parallel-clinical-trials-lead-drug-eftilagimod-alpha\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/immutep-improved-results-two-parallel-clinical-trials-lead-drug-eftilagimod-alpha\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immutep\u516c\u5e03\u4e86\u4e24\u4e2a\u5e73\u884c\u4e34\u5e8a\u8bd5\u9a8c\u5bf9\u5148\u5bfc\u836f\u7269eftilagimod alpha\u7684\u6539\u8fdb\u7ed3\u679c\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74\",\"name\":\"Small Caps\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g\",\"caption\":\"Small Caps\"},\"description\":\"Small Caps provides coverage on Australian ASX listed small cap stocks across all sectors: mining, resources, energy, biotech, technology, juniors and IPOs.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=5\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Immutep\u516c\u5e03\u4e86\u4e24\u4e2a\u5e73\u884c\u4e34\u5e8a\u8bd5\u9a8c\u5bf9\u5148\u5bfc\u836f\u7269eftilagimod alpha\u7684\u6539\u8fdb\u7ed3\u679c","description":"\u751f\u7269\u6280\u672f\u516c\u53f8Immutep (ASX: IMM)\u516c\u5e03\u4e86\u5176\u5148\u5bfc\u836f\u7269eftilagimod alpha\u7684\u4e24\u9879\u5e73\u884c\u4e34\u5e8a\u7814\u7a76\u7ed3\u679c\uff0c\u79f0\u201c\u6539\u5584\u7684\u7ed3\u679c\u201d\u548c\u201c\u4ee4\u4eba\u9f13\u821e\u7684\u201d\u65e9\u671f\u6297\u80bf\u7624\u6d3b\u6027\u6807\u5fd7\u7740\u5404\u79cd\u764c\u75c7\u9002\u5e94\u75c7\u5bf9\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242(ICI)\u6cbb\u7597\u4e0d\u654f\u611f\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Immutep\u516c\u5e03\u4e86\u4e24\u4e2a\u5e73\u884c\u4e34\u5e8a\u8bd5\u9a8c\u5bf9\u5148\u5bfc\u836f\u7269eftilagimod alpha\u7684\u6539\u8fdb\u7ed3\u679c","og_description":"\u751f\u7269\u6280\u672f\u516c\u53f8Immutep (ASX: IMM)\u516c\u5e03\u4e86\u5176\u5148\u5bfc\u836f\u7269eftilagimod alpha\u7684\u4e24\u9879\u5e73\u884c\u4e34\u5e8a\u7814\u7a76\u7ed3\u679c\uff0c\u79f0\u201c\u6539\u5584\u7684\u7ed3\u679c\u201d\u548c\u201c\u4ee4\u4eba\u9f13\u821e\u7684\u201d\u65e9\u671f\u6297\u80bf\u7624\u6d3b\u6027\u6807\u5fd7\u7740\u5404\u79cd\u764c\u75c7\u9002\u5e94\u75c7\u5bf9\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242(ICI)\u6cbb\u7597\u4e0d\u654f\u611f\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/immutep-improved-results-two-parallel-clinical-trials-lead-drug-eftilagimod-alpha\/","og_site_name":"smallcapsCN","article_published_time":"2020-09-17T23:10:15+00:00","article_modified_time":"2023-08-29T18:01:58+00:00","og_image":[{"url":"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/09\/Immutep-ASX-IMM-parallel-clinical-trials-lead-drug-eftilagimod-alpha-cancer.jpg"}],"author":"Small Caps","twitter_card":"summary_large_image","twitter_title":"Immutep\u516c\u5e03\u4e86\u4e24\u4e2a\u5e73\u884c\u4e34\u5e8a\u8bd5\u9a8c\u5bf9\u5148\u5bfc\u836f\u7269eftilagimod alpha\u7684\u6539\u8fdb\u7ed3\u679c","twitter_description":"\u751f\u7269\u6280\u672f\u516c\u53f8Immutep (ASX: IMM)\u516c\u5e03\u4e86\u5176\u5148\u5bfc\u836f\u7269eftilagimod alpha\u7684\u4e24\u9879\u5e73\u884c\u4e34\u5e8a\u7814\u7a76\u7ed3\u679c\uff0c\u79f0\u201c\u6539\u5584\u7684\u7ed3\u679c\u201d\u548c\u201c\u4ee4\u4eba\u9f13\u821e\u7684\u201d\u65e9\u671f\u6297\u80bf\u7624\u6d3b\u6027\u6807\u5fd7\u7740\u5404\u79cd\u764c\u75c7\u9002\u5e94\u75c7\u5bf9\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242(ICI)\u6cbb\u7597\u4e0d\u654f\u611f\u3002","twitter_image":"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/09\/Immutep-ASX-IMM-parallel-clinical-trials-lead-drug-eftilagimod-alpha-cancer.jpg","twitter_misc":{"Written by":"Small Caps"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/immutep-improved-results-two-parallel-clinical-trials-lead-drug-eftilagimod-alpha\/","url":"https:\/\/smallcapscn.x5view.co\/immutep-improved-results-two-parallel-clinical-trials-lead-drug-eftilagimod-alpha\/","name":"Immutep\u516c\u5e03\u4e86\u4e24\u4e2a\u5e73\u884c\u4e34\u5e8a\u8bd5\u9a8c\u5bf9\u5148\u5bfc\u836f\u7269eftilagimod alpha\u7684\u6539\u8fdb\u7ed3\u679c","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2020-09-17T23:10:15+00:00","dateModified":"2023-08-29T18:01:58+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74"},"description":"\u751f\u7269\u6280\u672f\u516c\u53f8Immutep (ASX: IMM)\u516c\u5e03\u4e86\u5176\u5148\u5bfc\u836f\u7269eftilagimod alpha\u7684\u4e24\u9879\u5e73\u884c\u4e34\u5e8a\u7814\u7a76\u7ed3\u679c\uff0c\u79f0\u201c\u6539\u5584\u7684\u7ed3\u679c\u201d\u548c\u201c\u4ee4\u4eba\u9f13\u821e\u7684\u201d\u65e9\u671f\u6297\u80bf\u7624\u6d3b\u6027\u6807\u5fd7\u7740\u5404\u79cd\u764c\u75c7\u9002\u5e94\u75c7\u5bf9\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242(ICI)\u6cbb\u7597\u4e0d\u654f\u611f\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/immutep-improved-results-two-parallel-clinical-trials-lead-drug-eftilagimod-alpha\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/immutep-improved-results-two-parallel-clinical-trials-lead-drug-eftilagimod-alpha\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/immutep-improved-results-two-parallel-clinical-trials-lead-drug-eftilagimod-alpha\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Immutep\u516c\u5e03\u4e86\u4e24\u4e2a\u5e73\u884c\u4e34\u5e8a\u8bd5\u9a8c\u5bf9\u5148\u5bfc\u836f\u7269eftilagimod alpha\u7684\u6539\u8fdb\u7ed3\u679c"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/ba96c5f4870849ab11e50adb62f2df74","name":"Small Caps","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5631bbe5d71ed71e3a6c301df6f973d0?s=96&d=mm&r=g","caption":"Small Caps"},"description":"Small Caps provides coverage on Australian ASX listed small cap stocks across all sectors: mining, resources, energy, biotech, technology, juniors and IPOs.","url":"https:\/\/smallcapscn.x5view.co\/?author=5"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/1955"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1955"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/1955\/revisions"}],"predecessor-version":[{"id":9406,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/1955\/revisions\/9406"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/9407"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1955"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1955"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1955"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}